Semi-automated vessel analysis software offered by five vendors tends to underestimate the degree of carotid stenosis, particularly at the higher levels that indicate a need for corrective action, according to a study presented at the RSNA meeting Sunday.
Semi-automated vessel analysis software offered by five vendors tends to underestimate the degree of carotid stenosis, particularly at the higher levels that indicate a need for corrective action, according to a study presented at the RSNA meeting Sunday.
Among the findings of a research team led by Dr. William Boonn: Underestimation of stenosis greater than 70% ranged from 12% to 50%.
Boonn, an imaging informatics fellow at VA Maryland Health Care System when the study was conducted, is now at the University of Pennsylvania.
Using semi-automated vessel analysis software led to significant variability and underestimation of carotid stenosis, the study concluded. These results, along with analysis failures, worsen as the percentage of stenosis increases.
Precise data for individual workstations and software packages were not disclosed during the presentation.
The study analyzed data from 23 carotid arteries from 12 patients undergoing carotid CT angiography using multislice CT. One artery was excluded as a result of postsurgical changes. The software measurements were compared with manual measurement of all 23 carotid arteries performed in consensus with a standard procedure described in recent literature and based on criteria in the North American Symptomatic Carotid Endarterectomy Trial (NASCET).
Users of semi-automated vessel analysis systems must select the vessel to be segmented and the segment to be analyzed, Boonn said. Automated results from six commercially available systems and packages from five vendors were compared with the manual measurements.
No variation in the manual and automated measurements appeared among the eight normals in the study group, Boonn said. But as the degree of stenosis increased, the variability increased as well, mostly in the form of underestimation.
This finding is critical, because the NASCET has shown that patients with high-grade stenosis can benefit from carotid endarterectomy.
Even with the underestimation of stenosis, vessel analysis systems offer some benefits, Boonn said. Segmentation can improve visualization, and curved multiplanar reformatting can help visualize tortuous vessels.
But the study's results suggest that vendors must improve the consistency and accuracy of automated stenosis measurements, according to Boonn.
"We advocate the use of publicly available standardized data sets that can be used by vendors to validate their measurements," he said.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
New DEXA Scan Study Links Thyroid Medication Levothyroxine to Higher Bone Loss Risk in Seniors
November 25th 2024Use of the medication levothyroxine, commonly prescribed for hypothyroidism, was associated with greater long-term loss of total body bone mass in seniors, according to new DEXA research to be presented at the Radiological Society of North America (RSNA) conference.
RSNA 2020: Addressing Healthcare Disparities and Access to Care
December 4th 2020Rich Heller, M.D., with Radiology Partners, and Lucy Spalluto, M.D., with Vanderbilt University School of Medicine, discuss the highlights of their RSNA 2020 session on health disparities, focusing on the underlying factors and challenges radiologists face to providing greater access to care.
Is Contrast-Enhanced Mammography a Viable Option for Diagnosing Invasive Lobular Carcinoma?
December 15th 2023Contrast-enhanced mammography had a 98 percent sensitivity rate for diagnosing invasive lobular carcinoma and provided high conspicuity for 82 percent of detected lesions, according to research presented at the recent Radiological Society of North America (RSNA) conference.
Can an Emerging PET Radiotracer Enhance Detection of Prostate Cancer Recurrence?
December 14th 2023The use of 68Ga-RM2 PET/MRI demonstrated a 35 percent higher sensitivity rate than MRI alone for the diagnosis of biochemical recurrence of prostate cancer, according to research recently presented at the Radiological Society of North America (RSNA) conference.